• Nie Znaleziono Wyników

The Voice of the Editor-in-Chief


Academic year: 2022

Share "The Voice of the Editor-in-Chief"

Pokaż więcej ( Stron)

Pełen tekst



The Voice of the Editor-in-Chief

Recently, I had the opportunity to participate in the Congress of the International Diabetes Federa- tion (IDF), which took place in Abu Dhabi from 4 to 8 December 2017 and gathered 8,000 delegates from 165 countries. The program of the meeting was very extensive and covered key issues of modern diabeto- logy. Many interesting reports presented during the Congress addressed, among others, epidemiology, new possibilities of molecular biology, measurable effects of translating basic science into everyday clinical practice, the problem of obesity and related insulin resistance, vascular complications of diabetes and new molecules whose introduction to diabetes treatment raises hope for optimization of therapy and improvement of the quality of life of patients, especially in the context of new results of the Cardiovascular Outcome Trial (CVOT).

During the Congress, I actively participated in a number of interesting scientific sessions devoted to the above topics, especially concerning the availability and use of new therapies and the broadly understood cardiovascular risk. The goal of diabetes treatment is to lower the blood glucose levels and ultimately to prevent complications associated with long-term tissue exposure to hyperglycaemia, but glycaemic control remains difficult and stimulates the search for new directions and effec- tive therapy. Moreover, in the context of new groups of antihyperglycaemic drugs and relevant results of CVOT, the question arises whether the philosophy of treatment based on the glucocentric approach should not change.

Our knowledge about diabetes is constantly deepe- ning and we have witnessed successive turning points in our understanding of the disease, treatment plans and available options for both therapy and self-control, but the more we learn, the more we are convinced that we are still far from obtaining the full knowledge.

Incretins and SGLT-2 inhibitors, which are still regarded as “new hypoglycaemic agents”, are a breakthrough in the treatment of diabetes. They allow not only good glycaemic control, but also significantly reduce cardio- vascular risk in patients with type 2 diabetes who are at high risk of cardiovascular events. During the meeting, the importance of individualization of treatment was frequently emphasized with regard to intensive treat- ment of type 2 diabetes patients. The problem of the intensive treatment of type 2 diabetes patients is all the more intriguing, that the impact of intense glycaemic control on the risk of macrovascular complications, including coronary vessels, is questionable. Therefore, in the context of the second CVOT, one may ask, “Is it time to change the approach to the treatment of type 2 diabetes? Is there really a class effect of incretins and SGLT2 inhibitors, despite the differences observed?”

The articles contained in the next issue of “Clinical Diabetology” also refer to the above issues, both in terms of vascular complications and diagnostic and therapeutic options, which I hope will provide support for you in everyday practice. I strongly encourage you to read our journal.


Prof. Janusz Gumprecht

Dear Colleagues,



Powiązane dokumenty

Przekazywał nam też hoj- nie swoje wiadomości, choć byliśmy w wieku, kiedy na ogół nie docenia się wielu skarbów pchających się w ręce.. Na szczęście zapamiętałam zdradzone

– Slavist researcher, theorist and historian of literature, comparatist, head of the Institute of Slavonic Studies at the Faculty of Arts, Masaryk University, Czech Republic,

„Rodzina w systemie wsparcia społecznego i pomocy osobom z problemem alkoholowym”, zorganizowana przez Pracownię Pedagogiki Specjalnej, w ramach realizowanego

Metod dwukierunkowej elektroforezy (2–DE) rozdzielono białka protoplastów ziaren pyłku dwóch samoniezgodnych odmian Amilo i Kier oraz dwóch samozgodnych linii (Ls190 i

Professor Janusz Gumprecht has excellently developed the journal — it appears regularly, contains more and more papers from outside Poland, is included in the Web of Science

Just before the publication of this issue of “Cli- nical Diabetology”, the largest diabetes meeting in the world — 79 th Scientific Sessions of the American Diabetes

Although more than 3,500 years have passed since the first description of the symptoms of diabetes in the Egyptian papyrus dated to around 1550 BC, diabetes is still

differences in the frequency, causes and duration of hospitalization of children with diabetes in different regions of Poland, which implies the need to ensure uniform access

Another challenge is effective and safe use of antidiabetic drugs to minimize side effects, improve adherence, increase the acceptance of the disease and reduce the risk

At the beginning of October, annual meeting of European Association for the Study of Diabetes (EASD) will be held in Berlin, and one of the most awaited events during this

Among papers included in this issue of “Clinical Diabetology”, it is worth paying attention to a multi- centre study conducted in 2013–2017 in women with type 1 diabetes who,

As the practical management of patients with diabetes should be based primarily on knowledge derived from Evidence Based Medicine (EBM), the reference to the EBM

I would like to draw your attention to the problem of diabetes care quality discussed by researchers from Libya, an interesting case report of the use of hydroxychloroquine in type

Following the publication of the results of already completed Cardiovascular Outcome Trials (CVOTs) on new molecules used in the treatment of diabetes, there is no doubt that

In the InTandem3 study (Study to Evaluate the Safety of So- tagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) with

In addition to attending the scientific meetings, I also encourage you to read the latest issue of the “Clinical Diabetology”, where, among a number of interesting articles, I would

Considering the above, I would like to draw your attention to two of many interesting articles published in the last issue of Clinical Diabetology: the paper presenting

In accordance with other diabetic organizations (the American Diabetes Association — ADA, the National Institute for Health and Care Excellence — NICE), glycaemic goals has

Here, it should be mentioned that also the LEADER trial, that assessed cardiovascular safety of one of GLP-1 agonists, liraglutide, in the population of type 2 diabetes

Despite recent advances in medicine, introduction of new hypoglycaemic drugs and the fact that more than 3.500 years have passed since the earliest known record of diabetes

The conference brought together a group of distinguished lecturers and almost 500 participants — physicians dealing in their everyday practice with carbohydrate

At the same time, we intend to continue the educational function of the journal and we do not want to hinder the access to its content for the readers; therefore, we decided

This change is a result of systematic de- velopment of our journal aiming at further increasing its presence and importance on the international arena and striving to